Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study

INTRODUCTION: In the phase 3 CASPIAN study, first-line durvalumab plus etoposide combined with either carboplatin or cisplatin (EP) significantly improved overall survival (OS) versus EP alone in treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC). We report exploratory subgroup analyses from CASPIAN. METHODS: Patients with untreated ES-SCLC were randomized to durvalumab plus EP or EP alone. We analyzed OS and safety in subgroups defined by age, sex, and planned platinum agent, and patient-reported outcomes (PROs) by age. RESULTS: Of 537 patients (durvalumab plus EP: n = 268; EP alone: n = 269), 80.6% versus 19.4% were aged <70 versus

• Reinmuth, N.
• Goldman, J. W.
• Chen, Y.
• Hotta, K.
• Trukhin, D.
• Statsenko, G.
• Hochmair, M.
• Özgüro
• Ji, J. H.
• Garassino, M. C.
• Poltoratskiy, A.
• Verderame, F.
• Havel, L.
• Bondarenko, I.
• Losonczy, G.
• Conev, N.
• Kummer, S.
• Mann, H.
• Chugh, P.
• Dalvi, T.
• Paz-Ares, L.